Merck presents new cardiovascular research at ACC.25, showcasing advancements and treatments

From Nasdaq: 2025-03-19 14:56:33

Merck & Co., Inc. (MRK) will showcase new research at ACC.25 in Chicago, focusing on cardiovascular disease advancements and treatments. Key presentations include Phase 3 ZENITH trial results for WINREVAIR in PAH patients. Merck will also present studies on cholesterol management, heart failure therapy, and economic evaluations of ASCVD treatment patterns. WINREVAIR, FDA-approved for PAH, improves vascular function but poses safety risks. Merck’s commitment to cardiovascular research aims to enhance patient outcomes. MRK stock currently trades at $94.08 on the NYSE.



Read more at Nasdaq: Merck Presents Key Cardiovascular Research Findings At ACC.25